Urological tumors in renal transplantation

Minerva Urologica e Nefrologica

Volumn 66, Issue 1, 2014, Pages 57-67

  Tillou, X ^a   Doerfler, A ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Kidney transplantation; Surgical procedures, operative; Urologic neoplasms

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PROSTATE SPECIFIC ANTIGEN;

BLADDER CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLEAR CELL CARCINOMA; CONSERVATIVE TREATMENT; CYSTECTOMY; DIALYSIS; ECHOGRAPHY; GRAFT CARCINOMA; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LAPAROSCOPIC RADICAL NEPHRECTOMY; LYMPH NODE DISSECTION; MYCOBACTERIUM BOVIS BCG; NEPHRECTOMY; PAPILLARY CARCINOMA; PATIENT MONITORING; PATIENT SAFETY; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT CANCER; UROGENITAL TRACT TUMOR;

HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; RISK FACTORS; UROLOGIC NEOPLASMS;

EID: 84901835279     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886-7. (Pubitemid 30311885)
2. Tsaur I, Karalis A, Probst M, Blaheta RA, Scheuermann EH, Gossmann J et al. Development of urological cancers in renal transplant recipients: 30-year experience at the Frankfurt Transplant Center. Cancer Sci 2010;101:2430-5.
3. Birkeland SA. De novo cancers complicating renal transplantation: experience in the Nordic countries. Ann Transplant 1997;2:22-6.
4. Lutz J, Heemann U. Tumours after kidney transplantation. Curr Opin Uro 2003;13:105-9. (Pubitemid 36288340)
5. Tillou X, Doerfler A, Collon S, Kleinclauss F, Patard JJ, Badet L et al. De novo kidney graft tumors: results from a multicentric retrospective national study. Am J Transplant 2012;12:3308-15.
6. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007;22 Suppl 1:i4-10.
7. O'Donnell C, Cutner A, Williams G. Metastatic native renal carcinoma in renal transplant recipients. Nephrol Dial Transplant 1988;3:690-3. (Pubitemid 19001004)
8. Ng RC, Suki WN. Renal cell carcinoma occurring in a polycystic kidney of a transplant recipient. J Urol 1980;124:710-2. (Pubitemid 11195785)
9. Doublet JD, Peraldi MN, Gattegno B, Thibault P, Sraer JD. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997;158:42-4. (Pubitemid 27251590)
10. Neuzillet Y, Lay F, Luccioni A, Daniel L, Berland Y, Coulange C et al. De novo renal cell carcinoma of native kidney in renal transplant recipients. Cancer 2005;103:251-7. (Pubitemid 40129283)
11. Ianhez LE, Lucon M, Nahas WC, Sabbaga E, Saldanha LB, Lucon AM et al. Renal cell carcinoma in renal transplant patients. Urology 2007;69:462-4. (Pubitemid 46428387)
12. Tillou X, Viart L, Demailly M, Hakami F, Westeel PF, Saint F et al. Results of nephrectomy for native kidney tumors in renal transplanted patients. Prog Urol 2011;21:322-6.
13. Tsaur I, Karalis A, Probst M, Blaheta RA, Scheuermann EH, Gossmann J et al. Development of urological cancers in renal transplant recipients: 30-year experience at the Frankfurt Transplant Center. Cancer Sci 2010;101:2430-5.
14. Suson KD, Sausville JE, Sener A, Phelan MW. Native nephrectomy for renal cell carcinoma in transplant recipients. Transplantation 2011;91:1376-9.
15. Penn I. Primary kidney tumors before and after renal transplantation. Transplantation 1995;59:480-5.
16. Gigante M, Neuzillet Y, Patard JJ, Tillou X, Thuret R, Branchereau J et al. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int 2012;110:E570-3.
17. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31. (Pubitemid 44969182)
18. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007;7:941-8. (Pubitemid 46481211)
19. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010;10:1889-96.
20. Elkentaoui H, Robert G, Pasticier G, Bernhard JC, Couzi L, Merville P et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology 2010;75:126-32.
21. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28-34.
22. Tillou X, Demailly M, Hakami F, Westeel PF, Saint F, Petit J. De novo renal carcinoma in renal transplant recipients: effect of early treatment. Transplant Proc 2009;41:3314-6.
23. Leveridge M, Musquera M, Evans A, Cardella C, Pei Y, Jewett M et al. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J Urol 2011;186:219-23.
24. Klatte T, Marberger M. Renal cell carcinoma of native kidneys in renal transplant patients. Curr Opin Urol 2011;21:376-9.
25. Viart L, Surga N, Collon S, Jaureguy M, Elalouf V, Tillou X. The high rate of de novo graft carcinomas in renal transplant recipients. Am J Nephrol 2013;37:91-6.
26. Goeman L, Joniau S, Oyen R, Van Poppel H. Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy. Urology 2006;67:199.
27. Shingleton WB, Sewell PE. Percutaneous cryoablation of renal cell carcinoma in a transplanted kidney. BJU Int 2002;90:137-8. (Pubitemid 34785815)
28. Alberts VP, Minnee RC, Bemelman FJ, van Donsela 2013;18:174-81.
29. Hevia V, Gomez V, Alvarez S, Diez Nicolas V, Gomez Del Canizo C, Orosa A et al. Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients. Case rep Transplant 2013;2013:196528.
30. Kleinclauss F, Gigante M, Neuzillet Y, Mouzin M, Terrier N, Salomon L et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant 2008;23:2374-80. (Pubitemid 351957601)
31. Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K et al. Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation 2003;75:237-9. (Pubitemid 36139680)
32. Hoda MR, Hamza A, Greco F, Wagner S, Reichelt O, Heynemann H et al. Management of localized prostate cancer by retropubic radical prostatectomy in patients after renal transplantation. Nephrol Dial Transplant 2010;25:3416-20.
33. Antonopoulos IM, Nahas WC, Piovesan AC, Falci R, Jr., Kanashiro H, Alvarez GA et al. Radical retropubic prostatectomy for localized prostate cancer in renal transplant patients. Urology 2008;72:1362-5.
34. Doerfler A, Vaessen C, Gosseine PN, Barrou B, Richard F. Laparoscopic radical prostatectomy in kidney transplant patient: our first experience-a case report. Transplant Proc 2009;41:713-5.
35. Robert G, Elkentaoui H, Pasticier G, Couzi L, Merville P, Ravaud A et al. Laparoscopic radical prostatectomy in renal transplant recipients. Urology 2009;74:683-7.
36. Thomas AA, Nguyen MM, Gill IS. Laparoscopic transperitoneal radical prostatectomy in renal transplant recipients: a review of three cases. Urology 2008;71:205-8. (Pubitemid 351282372)
37. Mouzin M, Bachaud JM, Kamar N, Game X, Vaessen C, Rischmann P et al. Three-dimensional conformal radiotherapy for localized prostate cancer in kidney transplant recipients. Transplantation 2004;78:1496-500. (Pubitemid 39552936)
38. Detti B, Scoccianti S, Franceschini D, Villari D, Greto D, Cipressi S et al. Adjuvant radiotherapy for a prostate cancer after renal transplantation and review of the literature. Jpn J Clin Oncol 2011;41:1282-6.
39. Coombs CC, Hertzfeld K, Barrett W. Outcomes in transplant patients undergoing brachytherapy for prostate cancer. Am J Clin Oncol 2012;35:40-4.
40. U XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 2008;15:53-7.
41. Liao CH, Chueh SC, Lai MK, Chen J. Transitional cell carcinoma in renal transplant recipients. Transplant Proc 2004;36:2152-3. (Pubitemid 39424361)
42. Wu MJ, Lian JD, Yang CR, Cheng CH, Chen CH, Lee WC et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004;43:1091-7. (Pubitemid 38691505)
43. Ye J, Ma L, Huang Y, Hou X, Xiao C, Zhao L et al. Retroperitoneal laparoscopic nephroureterectomy with bladder cuff excision for native upper tract transitional cell carcinoma ipsilateral to a transplanted kidney. Urology 2010;76:1395-9.
44. Chiang YJ, Chu SH, Liu KL, Lai WJ, Wang HH. Silent urothelial cancer detected by sonography after renal transplantation. Transplant Proc 2006;38:2084-5.
45. Nakazawa R, Miyano S, Sasaki H, Kudo H, Kimura K, Chikaraishi T. Synchronous bilateral urothelial cancer in a kidney recipient. Int J Urol 2011;18:847-50.
46. Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urology 1997;50:525-8. (Pubitemid 27433210)
47. Muruve NA, Shoskes DA. Genitourinary malignancies in solid organ transplant recipients. Transplantation 2005;80:709-16. (Pubitemid 41443750)
48. Master VA, Meng MV, Grossfeld GD, Koppie TM, Hirose R, Carroll PR. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol 2004;171:1085-8. (Pubitemid 38327532)
49. Neuzillet Y, Cabaniols L, Karam G, Salomon L, Barrou B, Petit J et al. Study of urothelial bladder tumours in renal transplant recipients. Prog Urol 2006;16:343-6. (Pubitemid 44911977)
50. Zhou M, Zhu Y, Wang L, Wang Y, Fu S, Min Z. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases. Clin Transpl 2006:395-8.
51. Kao YL, Ou YC, Yang CR, Ho HC, Su CK, Shu KH. Transitional cell carcinoma in renal transplant recipients. World J Surg 2003;27:912-6.
52. Rogers A, Ng JK, Glendinning J, Rix D. The management of transitional cell carcinoma (TCC) in a European regional renal transplant population. BJU Int 2012;110:E34-40.
53. Palou J, Angerri O, Segarra J, Caparros J, Guirado L, Diaz JM et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003;76:1514-6. (Pubitemid 37467704)
54. Tillou X, Raynal G, Limani K, Saint F, Petit J. Carcinoma in situ in bladder and urethra among renal transplanted patient: failure of BCG therapy. Prog Urol 2008;18:1097-9.
55. Manassero F, Di Paola G, Mogorovich A, Giannarini G, Boggi U, Selli C. Orthotopic bladder substitute in renal transplant recipients: experience with Studer technique and literature review. Transplant Int 2011;24:943-8.
56. Ducloux D, Carron PL, Motte G, Ab A, Rebibou JM, Bresson-Vautrin C et al. Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transplant Int 2002;15:393-6. (Pubitemid 36061753)
57. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009;10:1152-9.
58. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004;77:1777-82. (Pubitemid 38822196)
59. Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 2005;65:2947-55. (Pubitemid 40490100)
60. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
61. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B et al. Tacrolimus enhances transforming growth factor-betal expression and promotes tumor progression. Transplantation 2003;76:597-602. (Pubitemid 37013269)
62. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Ntl Cancer Inst 1995;87:1456-62.
63. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-8. (Pubitemid 28098444)
64. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4. (Pubitemid 41325100)
65. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005;5:2954-60. (Pubitemid 43923957)
66. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723-8.
67. Geissler EK. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients? Transplant Proc 2010;42:S32-5.
68. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9. (Pubitemid 41552882)
69. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73(:1565-72.
70. van der Poel HG, Hanrahan C, Zhong H, Simons JW. Rapamycin induces Smad activity in prostate cancer cell lines. Urological research 2003;30:380-6. (Pubitemid 36285655)
71. Elkentaoui H, Robert G, Pasticier G, Bernhard JC, Couzi L, Merville P et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology.75:126-32.
72. Melchior S, Franzaring L, Shardan A, Schwenke C, Plumpe A, Schnell R et al. Urological de novo malignancy after kidney transplantation: a case for the urologist. J Urol.185:428-32.
73. Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol 60:366-73.
74. Cussenot O, Fournier G. Genetics and urology. Prog Urol 2000;10:681-1097.
75. Verine J, Varna M, Ratajczak P, El-Bouchtaoui M, Leboeuf C, Plassa LF et al. Human de novo papillary renal-cell carcinomas in a kidney graft: evidence of recipient origin with adenoma-carcinoma sequence. Am J Transplant 2013;13:984-92.
76. Roupret M, Peraldi MN, Thaunat O, Chretien Y, Thiounn N, Dufour B et al. Renal cell carcinoma of the grafted kidney: how to improve screening and graft tracking. Transplantation 2004;77:146-8. (Pubitemid 38116890)
77. Chambade D, Meria P, Tariel E, Verine J, De Kerviler E, Peraldi MN et al. Nephron sparing surgery is a feasible and efficient treatment of T1a renal cell carcinoma in kidney transplant: a prospective series from a single center.J Urol 2008;180:2106-9.
78. Cherif M, Rouache L, Tapon E, Pfister C. Usefulness of an inline radiofrequency device in renal allograft preserving surgery. Transplantation 2007;83:522-3. (Pubitemid 46667859)
79. Greco AJ, Baluarte JH, Meyers KE, Sellers MT, Suchi M, Biegel JA et al. Chromophobe renal cell carcinoma in a pediatric living-related kidney transplant recipient. Am J Kidney Dis 2005;45:105-8.
80. Hetet JF, Rigaud J, Dorel-Le Theo M, Laute F, Karam G, Blanchet P. De novo tumours of renal transplants. Ann Urol 2007;41:285-97.
81. Di Capua Sacoto C, Lujan Marco S, Bahilo Mateu P, Budia Alba A, Pontones Moreno JL, Jimenez Cruz JF. De novo urological neoplasms in kidney transplant patients: experience in 1,751 patients. Actas Urol Esp 34:88-94.
82. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007;7:2140-51. (Pubitemid 47247055)
83. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-92. (Pubitemid 30354515)
84. Noel JC, Peny MO, Mat O, Antoine M, Firket C, Detremmerie O et al. Human papillomavirus type 16 associated with multifocal transitional cell carcinomas of the bladder in two transplanted patients. Transplant Int 1994;7:340-3. (Pubitemid 24261024)
85. Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R et al. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. Urol Int 2012;89:61-6.
86. Neuzillet Y, Davin JL, Lechevallier E. Intravesical BCG instillations for the treatment of superficial bladder tumours in renal transplant recipients. Prog Urol 2006;16:32-5. (Pubitemid 44726026)
87. Melchior S, Franzaring L, Shardan A, Schwenke C, Plumpe A, Schnell R et al. Urological de novo malignancy after kidney transplantation: a case for the urologist. J Urol 2011;185:428-32.
88. De Broe ME. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int 2012;81:513-5.
89. Kalble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M. EAU guidelines on renal transplantation. Eur Urol 2005;47:156-66. (Pubitemid 40126971)
90. Tremblay F, Fernandes M, Habbab F, de BEMD, Loertscher R, Meterissian S. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 2002;9:785-8.
91. Geissler EK, Schlitt HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int.78:1075-9.
92. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9 Suppl 3:S1-155.
93. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Brit J Radiol 2008;81:362-78. (Pubitemid 351743850)